The disappearance of inflammatory lesions of the spine between baseline and week 24 during adalimumab therapy and the development of new lesions by anatomical location
| Lesion type | Disappearance: number of lesions no longer present at week 24/number of lesions present at baseline (%) | Development: number of lesions present at week 24 but not at baseline/number of baseline zero scores (%) | Disappearance: number of patients with disappearance of at least one lesion at week 24 (%) | Development: number of patients with development of at least one lesion at week 24 (%) |
| Anterior corner lesions | 107/159 (67) | 7/1657 (0.4) | 23/42 (55) | 3/42 (7) |
| Posterior corner lesions | 38/54 (70) | 3/1766 (0.2) | 14/42 (33) | 2/42 (5) |
| Non-corner lesions | 15/27 (56) | 1/1789 (0.1) | 6/42 (14) | 1/42 (2) |
| Antero-lateral corner lesions | 41/53 (77) | 3/2571 (0.1) | 14/42 (33) | 3/42 (7) |
| Postero-lateral corner lesions | 58/69 (84) | 3/2563 (0.1) | 14/42 (33) | 1/42 (2) |
| Transverse processes/ribs | 3/4 (75) | 3/1312 (0.2) | 2/42 (5) | 2/42 (5) |
| Facet joints | 18/26 (69) | 3/1794 (0.2) | 5/42 (12) | 2/42 (5) |
| Spinous processes | 1/2 (50) | 0/908 (0.0) | 1/42 (2) | 0/42 (0) |
| Soft tissue | 0/0 (NA) | 0/910 (0.0) | 0/42 (0) | 0/42 (0) |
NA, not available.